Abstract

REVIEW ON ANALYTICAL METHOD DEVELOPMENT AND VALIDATION BY HPLC/LC-MS OF SELECTED ANTI-CANCER DRUGS

M. Rajavardhan Reddy* and R. Suresh

ABSTRACT

In this review article determines the different analytical methods for the quantitative estsblishement of selected tyrosine kinase inhibitors (Imatinib mesylate, Nilotinib and Dasatinib) by using HPLC, HPLC-MS, HPLC-UV, LC-MS/MS. Pharmaceutical analytical method developement of tyrosine kinase inhibitors (Imatinib Mesylate, Nilotinib and Dasatinib) requires valid analytical procedures for quantitative and qualitative analysis in Pharmaceuticals dosage formulations and human serum. An Huge survey for determination of TKI (Imatinib Mesylate, Nilotinib and Dasatinib) follow from the research articles published in various pharmaceutical and analytical chemistry Journals. This assessment explain that the superiority of the HPLC/LC-MS methods reviewed is based on the quantitative analysis of drugs in formulations, (API), biological fluids such as serum and plasma.

Keywords: Method development, High performance Liquid Chromatography (HPLC/LC-MS), (Imatinib Mesylate, Nilotinib and Dasatinib).